Goichi Yoshimoto
Overview
Explore the profile of Goichi Yoshimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugio T, Miyawaki K, Uchida N, Niemann M, Spierings E, Mori K, et al.
Br J Haematol
. 2025 Mar;
PMID: 40065633
Cord blood transplantation (CBT) is a valuable donor source for patients without human leukocyte antigen (HLA)-matched donors. While CBT has a lower risk of graft-versus-host disease and requires less stringent...
2.
Goto T, Numata H, Katsuoka Y, Uoshima N, Hara S, Ando J, et al.
Oncol Ther
. 2025 Mar;
PMID: 40055300
Introduction: Venetoclax has demonstrated clinical benefit for newly-diagnosed acute myeloid leukemia (AML), but significant neutropenia is a concern. Data on the time course of neutrophil counts for across treatment cycles...
3.
Iyama S, Chi S, Idogawa M, Ikezoe T, Fukushima K, Utsu Y, et al.
Ann Hematol
. 2025 Feb;
104(1):275-284.
PMID: 39921715
Ten-eleven translocation-2 (TET2) gene mutations are observed in 12-20% of adult patients with acute myeloid leukemia (AML). The prognostic impact of TET2 mutations in patients with AML and myelodysplastic syndromes...
4.
Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y, et al.
Cancer Sci
. 2024 Dec;
116(3):698-709.
PMID: 39726280
In this study, we investigated the measurable residual leukemic stem cell (MR-LSC) population after allogeneic stem cell transplantation (allo-SCT) for high-risk acute myeloid leukemia (AML), utilizing T-cell immunoglobulin mucin-3 (TIM-3)...
5.
Arai H, Hosono N, Chi S, Fukushima K, Ikeda D, Iyama S, et al.
Int J Hematol
. 2024 Dec;
121(3):378-387.
PMID: 39680349
HM-SCREEN-Japan is a multicenter collaborative project in Japan to evaluate the clinical utility of a cancer genome panel in the treatment of acute myeloid leukemia (AML). The HM-SCREEN-JAPAN02 study used...
6.
Shima T, Minami M, Tochigi T, Kochi Y, Jinnouchi F, Yamauchi T, et al.
Blood Cell Ther
. 2024 Jun;
7(2):49-55.
PMID: 38854399
Infection is a major contributor to non-relapse mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Detecting infectious diseases in febrile patients during pretransplant conditioning is crucial for subsequent transplant success....
7.
Sugio T, Uchida N, Miyawaki K, Ohno Y, Eto T, Mori Y, et al.
Bone Marrow Transplant
. 2024 Jan;
59(4):466-472.
PMID: 38238452
The "human leukocyte antigen (HLA) supertype" is a functional classification of HLA alleles, which was defined by structural features and peptide specificities, and has been reportedly associated with the clinical...
8.
Mori Y, Uchida N, Wake A, Miyawaki K, Eto T, Nakamura T, et al.
Vaccine
. 2023 Oct;
41(47):6899-6903.
PMID: 37866994
This prospective observational study aimed to assess the serological response and safety after the third booster shot of SARS-CoV-2 mRNA vaccines in 292 hematopoietic cell transplant (HCT) recipients. In our...
9.
Yoshimoto G, Miyamoto T
Rinsho Ketsueki
. 2023 Jul;
64(6):533-546.
PMID: 37407479
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has improved survival for patients with hematological malignancy, especially for those highly at risk of relapse. However, disease relapse after allo-HSCT remains the most...
10.
Mori Y, Uchida N, Harada T, Katayama Y, Wake A, Iwasaki H, et al.
Am J Hematol
. 2022 Oct;
98(1):102-111.
PMID: 36260658
HCT recipients reportedly have a high mortality rate after developing COVID-19. SARS-CoV-2 vaccination is generally useful to prevent COVID-19. However, its safety and efficacy among HCT recipients remain elusive. This...